Location of Repository

Regulation and Pharmacological Manipulation of the Type 5 Metabotropic Glutamate (mGlu5) Receptor

By Sophie Jane Bradley


Compelling evidence has emerged to indicate that astrocytes play crucial roles in neurotransmitter signalling, in addition to CNS homeostatic functions. Astrocytes can communicate with each other and with neurons, giving rise to the concept of the ‘tripartite synapse’. Expression of type 5 metabotropic glutamate (mGlu5) receptors in astrocytes is now well-established. Agonist stimulation of mGlu5 receptors initiates robust oscillatory changes in cytosolic Ca2+ concentration in single cells by rapid, repeated cycles of phosphorylation/dephosphorylation of the mGlu5 receptor, involving PKC and unidentified protein phosphatase activities in recombinant and native mGlu5 receptor-expressing systems. \ud Each of the mGlu5 receptor positive allosteric modulators (PAMs) studied (DFB, CPPHA, CDPPB and ADX47273), failed to stimulate a Ca2+ response when applied alone, but increased the frequency of Ca2+ oscillations induced by glutamate or other orthosteric agonists. PAMs and negative allosteric modulators (NAMs) caused respectively graded increases and decreases in the Ca2+ oscillation frequency stimulated by orthosteric agonist. These data demonstrate that allosteric modulators can “tune” the Ca2+ oscillation frequency initiated by mGlu5 receptor activation and this might allow pharmacological modification of the downstream processes (e.g. transcriptional regulation) not achievable through orthosteric ligand interactions. Further investigation into the mechanism of action of PAMs revealed marked differences with respect to their modulation of orthosteric agonist affinity and efficacy. Thus, while DFB and CDPPB primarily exert their allosteric modulatory effects through modifying orthosteric agonist affinity, effects of ADX47273 are primarily mediated through an efficacy-driven modulation. \ud Investigating the mechanisms underlying mGlu5 receptor-mediated Ca2+ oscillations in astrocytes has provided further evidence for the involvement of PKC(s) and protein phosphatase(s) in the rapid phosphorylation/dephosphorylation cycles occurring at the C-terminal of mGlu5 receptors, a process termed ‘dynamic uncoupling’. This work has been extended using specific siRNA knockdown to elucidate the potential PKC isoenzyme(s) that determine mGlu5 receptor regulation of Ca2+ oscillation frequency in astrocytes

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/9391

Suggested articles



  1. (1997). (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus.
  2. (1999). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.
  3. (2003). 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.
  4. (2002). 3H]Methoxymethyl-3-[(2-methyl1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization.
  5. (1999). A and Wise A
  6. (2005). A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.
  7. (1998). A cluster of basic residues in the carboxyl-terminal tail of the short metabotropic glutamate receptor 1 variants impairs their coupling to phospholipase C.
  8. (2003). A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
  9. (1992). A family of metabotropic glutamate receptors.
  10. (2010). A genetically targeted optical sensor to monitor calcium signals in astrocyte processes.
  11. (2002). A model for the functioning of family 3 GPCRs.
  12. (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.
  13. (1993). A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor.
  14. (1987). A new type of glutamate receptor linked to inositol phospholipid metabolism.
  15. (1996). A novel class of antagonists for metabotropic glutamate receptors, 7 (Hydroxyimino)cyclopropa[b] chromen-1a-carboxylates.
  16. (2006). A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators.
  17. (1995). A novel metabotropic glutamate receptor expressed in the retina and olfactory bulb.
  18. (2004). A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain.
  19. (2005). A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
  20. (1997). A novel splice variant of a metabotropic glutamate receptor, human mGluR7b.
  21. (1993). A pharmacological characterization of the mGluR1 alpha subtype of the metabotropic glutamate receptor expressed in a cloned baby hamster kidney cell line.
  22. (2011). A proteomic analysis of PKCepsilon targets in astrocytes: implications for astrogliosis.
  23. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.
  24. (1993). A variant of metabotropic glutamate receptor subtype 5: an evolutionally conserved insertion with no termination codon.
  25. (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.
  26. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome.
  27. (2003). Acetylcholine induces Ca 2+ oscillations via m3/m4 muscarinic receptors in the mouse oocyte.
  28. (2001). Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5.
  29. (2008). Activated nuclear metabotropic glutamate receptor mGlu5 couples to nuclear Gq/11 proteins to generate inositol 1,4,5-trisphosphate-mediated nuclear Ca 2+ release.
  30. (2009). Activation of group I metabotropic glutamate receptors leads to brain-derived neurotrophic factor expression in rat C6 cells.
  31. (2005). Activation of metabotropic glutamate receptor 1 dimers requires glutamate binding in both subunits.
  32. (2000). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.
  33. (2003). Activation of metabotropic glutamate receptor mGlu5 on nuclear membranes mediates intranuclear Ca 2+ changes in heterologous cell types and neurons.
  34. (2009). Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
  35. (1993). Activation of metabotropic glutamate receptors produces reciprocal regulation of ionotropic glutamate and GABA responses in the nucleus of the tractus solitarius of the rat.
  36. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
  37. (2001). Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6.
  38. (1999). Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors.
  39. (2005). Acute insult of ammonia leads to calciumdependent glutamate release from cultured astrocytes, an effect of pH.
  40. (2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ.
  41. (2008). ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
  42. (2006). Age-related emotionality is associated with cortical delta-opioid receptor dysfunction-dependent astrogliosis.
  43. (1995). Agonist mediated phosphorylation of metabotropic glutamate receptor 1 alpha by protein kinase C in permanently transfected BHK cells. Biochem Soc Trans 23:88S.
  44. (2001). Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer.
  45. (2001). Agonist-induced internalization of the metabotropic glutamate receptor 1a is arrestin- and dynamindependent.
  46. (1998). Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
  47. (1991). Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus.
  48. (2006). Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.
  49. (2002). Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov
  50. (2001). Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function.
  51. (2004). Allosteric modulation of G protein-coupled receptors.
  52. (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
  53. (2011). Allosteric modulation of G proteincoupled receptors: a pharmacological perspective.
  54. (2003). Allosteric modulators of G-protein-coupled receptors.
  55. (2002). Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.
  56. (2008). Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells.
  57. (2005). Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes.
  58. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation.
  59. (1992). Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in Xenopus oocytes.
  60. (2006). Alternative splicing of human metabotropic glutamate receptor 3.
  61. (2002). Alternative splicing unmasks dendritic and axonal targeting signals in metabotropic glutamate receptor 1.
  62. (2003). Amino acid mutagenesis of the ligand binding site and the dimer interface of the metabotropic glutamate receptor 1. Identification of crucial residues for setting the activated state.
  63. (1993). AMPA-selective glutamate receptor subunits in astroglial cultures.
  64. (2000). Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminaltruncated Abeta deposits in the human entorhinal cortex.
  65. (1997). An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors.
  66. (2005). An astrocytic basis of epilepsy.
  67. (2009). and Pilc A
  68. (2007). and Volterra A
  69. (1989). Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins.
  70. (1994). Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured Purkinje cells.
  71. (2006). Astrocyte dysfunction in neurological disorders: a molecular perspective.
  72. (2000). Astrocyte glutamate transport: review of properties, regulation, and physiological functions.
  73. (2007). Astrocyte glycogen and brain energy metabolism.
  74. (2010). Astrocyte heterogeneity: an underappreciated topic in neurobiology.
  75. (2007). Astrocyte metabolism and signaling during brain ischemia.
  76. (2006). Astrocyte-mediated control of cerebral blood flow.
  77. (2000). Astrocytes in the hippocampus of patients with temporal lobe epilepsy display changes in potassium conductances.
  78. (2007). Astrocytes play a critical role in transient heterosynaptic depression in the rat hippocampal CA1 region.
  79. (2005). Astrocytes protect neurons from ammonia toxicity.
  80. (2010). Astrocytes: biology and pathology.
  81. (2005). Astrocytic purinergic signaling coordinates synaptic networks.
  82. (2006). Astroglial heterogeneity closely reflects the neuronal-defined anatomy of the adult murine CNS.
  83. (2008). Astroglial metabolic networks sustain hippocampal synaptic transmission.
  84. (2005). Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators.
  85. (2001). BAY36-7620: a potent noncompetitive mGlu1 receptor antagonist with inverse agonist activity.
  86. (2008). Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction.
  87. (1999). Betaarrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.
  88. (2011). Bidirectional control of arteriole diameter by astrocytes.
  89. (2003). Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors.
  90. (2002). Bioinformatics and type II G-protein-coupled receptors.
  91. (2002). Ca -sensing receptor require negative feedback by protein kinase C.
  92. (2008). Ca 2+ oscillation frequency regulates agonist-stimulated gene expression in vascular endothelial cells.
  93. (2008). Ca 2+ oscillation induced by P2Y2 receptor activation and its regulation by a neuron-specific subtype of PKC (gammaPKC).
  94. (1991). Ca 2+ waves in astrocytes.
  95. (1999). Ca(2+)](i) oscillation frequency regulates agonist-stimulated NF-kappaB transcriptional activity.
  96. (2002). Calcium oscillations encoding neuron-to-astrocyte communication.
  97. (1998). Calcium oscillations increase the efficiency and specificity of gene expression.
  98. (2002). Calcium sensing receptor activation by a calcimimetic suggests a link between cooperativity and intracellular calcium oscillations.
  99. (2010). cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3.
  100. (2001). Cell type-specific differences in the coupling of recombinant mGlu1alpha receptors to endogenous G protein sub-populations.
  101. (1998). Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression.
  102. (2007). Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.
  103. Challiss RA and Nahorski SR (2001a) Reassessment of the Ca 2+ sensing property of a type I metabotropic glutamate receptor by simultaneous measurement of inositol 1,4,5-trisphosphate and Ca 2+ in single cells.
  104. Challiss RA and Nahorski SR (2001b) Intracellular signalling. Receptor-specific messenger oscillations.
  105. (1996). Changes in extracellular amino acid neurotransmitters and purines during and following ischemias of different durations in the rat cerebral cortex.
  106. (1994). Changes in metabotropic glutamate receptor mRNA levels following global ischemia: increase of a putative presynaptic subtype (mGluR4) in highly vulnerable rat brain areas.
  107. (1996). Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity.
  108. (2000). Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections.
  109. (1990). Characterization of the binding domain of the betaadrenergic receptor with the fluorescent antagonist carazolol. Evidence for a buried ligand binding site.
  110. (1999). Characterization of the dimerization of metabotropic glutamate receptors using an N-terminal truncation of mGluR1alpha.
  111. (2002). Characterization of three novel isoforms of the metabotrobic glutamate receptor 7 (GRM7).
  112. (2002). Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
  113. (1998). Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8.
  114. (1995). Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.
  115. (1999). Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8.
  116. (1999). Cloning of novel splice variants of mouse mGluR1.
  117. (1991). Cloning, expression, and gene structure of a G proteincoupled glutamate receptor from rat brain.
  118. (2004). Closed state of both binding domains of homodimeric mGlu receptors is required for full activity.
  119. (2003). Comparison of prefrontal cell pathology between depression and alcohol dependence.
  120. (2009). Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
  121. (2000). Complex involvement of pertussis toxin-sensitive G proteins in the regulation of type 1alpha metabotropic glutamate receptor signaling in baby hamster kidney cells.
  122. (2004). Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease.
  123. (2001). Control of astrocyte Ca( 2+ ) oscillations and waves by oscillating translocation and activation of protein kinase C.
  124. (1996). Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors.
  125. (2001). Control of synapse number by glia.
  126. (2007). Correction of fragile X syndrome in mice.
  127. (2008). Cortical layer 1 and layer 2/3 astrocytes exhibit distinct calcium dynamics in vivo. PLoS One 3:e2525.
  128. (2006). Coupling of agonist binding to effector domain activation in metabotropic glutamatelike receptors.
  129. (2001). Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization.
  130. (1999). CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.
  131. (2000). Crystal structure of rhodopsin: A G protein-coupled receptor.
  132. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.
  133. (2008). Crystal structure of the ligand-free G-protein-coupled receptor opsin.
  134. (2009). Cultured astrocytes derived from corpus callosum or cortical grey matter show distinct glutamate handling properties.
  135. (2001). Cytosolic calcium oscillations in astrocytes may regulate exocytotic release of glutamate.
  136. (1998). D-serine added to antipsychotics for the treatment of schizophrenia.
  137. (1997). Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure.
  138. (2000). Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer1 proteins and neuronal excitation.
  139. (1995). Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
  140. (2002). Determinants of metabotropic glutamate receptor-5-mediated Ca 2+ and inositol 1,4,5-trisphosphate oscillation frequency. Receptor density versus agonist concentration.
  141. (2006). Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors.
  142. (2005). Determination of the minimal functional ligand-binding domain of the GABAB1b receptor.
  143. (1994). Developmental expression of protein kinase C isozymes in oligodendrocytes and their differential modulation by 4 beta-phorbol12,13-dibutyrate.
  144. (1999). DHPG-induced LTD in area CA1 of juvenile rat hippocampus; characterisation and sensitivity to novel mGlu receptor antagonists.
  145. (1998). Differential modulation of adenylyl cyclases I and II by various G beta subunits.
  146. (1997). Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites.
  147. (1997). Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus.
  148. (2008). Differential roles of the PKC novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. PLoS One 3:e3793.
  149. (2001). Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey Substantia nigra.
  150. (1998). Dimerization of the extracellular calciumsensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells.
  151. (1982). Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumorpromoting phorbol esters.
  152. (2008). Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors.
  153. (1994). Direct signaling from astrocytes to neurons in cultures of mammalian brain cells.
  154. (2000). Directed spatial potassium redistribution in rat neocortex.
  155. (2009). Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype.
  156. (2010). Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.
  157. (2011). Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu(5)). Bioorg Med Chem Lett Varney
  158. (1999). Dissection of astrocyte-mediated cues in neuronal guidance and process extension.
  159. (1995). Distinct aspects of neuronal differentiation encoded by frequency of spontaneous Ca 2+ transients.
  160. (2001). Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites.
  161. (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain.
  162. (1992). Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat.
  163. (1998). Diversity of calcium signaling by metabotropic glutamate receptors.
  164. (2010). Do astrocytes really exocytose neurotransmitters?
  165. (1994). Domains involved in the specificity of G protein activation in phospholipase C-coupled metabotropic glutamate receptors.
  166. (2007). Effect of histone acetylation modification with sodium butyrate, a histone deacetylase inhibitor, on cell cycle, apoptosis, ploidy and gene expression in porcine fetal fibroblasts.
  167. (1964). Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain.
  168. (1998). Effects of human type 1alpha metabotropic glutamate receptor expression level on phosphoinositide and Ca 2+ signalling in an inducible cell expression system.
  169. (2009). Effects of Positive Allosteric Modulators on Single Cell Oscillatory Ca oscillations in rat cerebrocortical astroglia. 3rd Focused Meeting Cell Signalling
  170. (2009). Effects of positive allosteric modulators on single-cell oscillatory Ca 2+ signaling initiated by the type 5 metabotropic glutamate receptor.
  171. (1982). Effects of sodium butyrate, a new pharmacological agent, on cells in culture.
  172. (1999). Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists.
  173. (2005). Emerging complexities in identity and function of glial connexins.
  174. (1999). Endogenous activation of metabotropic glutamate receptors in neocortical development causes neuronal calcium oscillations.
  175. (2008). Endogenous homer proteins regulate metabotropic glutamate receptor signaling in neurons.
  176. (2004). Energy transfer from astrocytes to axons: the role of CNS glycogen.
  177. (1996). Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: protein, mRNA splice variants, and regional distribution.
  178. (1997). Enhanced type 1alpha metabotropic glutamate receptor-stimulated phosphoinositide signaling after pertussis toxin treatment.
  179. (1998). Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase.
  180. (1988). Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.
  181. (2005). Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR.
  182. (2003). Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors.
  183. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling.
  184. (1997). Excitatory synapses. Glutamate receptors put in their place.
  185. (2007). Exocytotic release of ATP from cultured astrocytes.
  186. (2003). Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins.
  187. (1998). Expression and purification of the extracellular ligand binding region of metabotropic glutamate receptor subtype 1.
  188. (1999). Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia.
  189. (1999). Expression and translocation of protein kinase C isoforms in rat microglial and astroglial cultures.
  190. (1997). Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors.
  191. (2005). Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
  192. (1994). Fingerprinting G-protein-coupled receptors.
  193. (1990). Fluorescence measurement of changes in intracellular calcium induced by excitatory amino acids in cultured cortical astrocytes.
  194. (1998). Frizzled proteins constitute a novel family of G protein-coupled receptors, most closely related to the secretin family. Trends Pharmacol Sci
  195. (2009). From promiscuity to precision: protein phosphatases get a makeover.
  196. (2010). Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator.
  197. (2002). G protein-coupled receptor allosterism and complexing.
  198. (2000). G protein-coupled receptor kinase-mediated desensitization of metabotropic glutamate receptor 1A protects against cell death.
  199. (2003). G protein-coupled receptor kinases regulate metabotropic glutamate receptor 5 function and expression.
  200. (1998). G protein-coupled receptors. II. Mechanism of agonist activation.
  201. (2006). G-protein-coupled receptors: past, present and future.
  202. (1999). G-protein-independent signaling mediated by metabotropic glutamate receptors.
  203. (2003). G-proteins as transducers in transmembrane signalling.
  204. (2008). G(12)/G(13)-mediated signalling in mammalian physiology and disease.
  205. (2000). GABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates.
  206. (2006). GABAergic network activation of glial cells underlies hippocampal heterosynaptic depression.
  207. (1994). GCRDb: a G-protein-coupled receptor database.
  208. (1995). Get receptive to metabotropic glutamate receptors.
  209. (2010). Glial calcium and diseases of the nervous system.
  210. (2004). Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia.
  211. (2003). Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex.
  212. (2002). Glial membrane channels and receptors in epilepsy: impact for generation and spread of seizure activity.
  213. (2007). Glial regulation of the cerebral microvasculature.
  214. (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis.
  215. (2008). Glutamate elicits release of BDNF from basal forebrain astrocytes in a process dependent on metabotropic receptors and the PLC pathway.
  216. (1990). Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling.
  217. (2005). Glutamate receptor activation triggers a calcium-dependent and SNARE proteindependent release of the gliotransmitter D-serine.
  218. (1990). Glutamate receptors activate Ca 2+ mobilization and Ca 2+ influx into astrocytes.
  219. (1998). Glutamate receptors in the mammalian central nervous system.
  220. (1998). Glutamate receptors: brain function and signal transduction.
  221. (1985). Glutamate stimulates inositol phosphate formation in striatal neurones.
  222. (1995). Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry.
  223. (2006). Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.
  224. (1994). Glutamate-mediated astrocyte-neuron signalling.
  225. (2007). Glutamate-mediated neuronal-glial transmission.
  226. (2002). Glutamatergic mechanisms in schizophrenia.
  227. (1984). Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy.
  228. (1995). Glycine transporters are differentially expressed among CNS cells.
  229. (2010). Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease.
  230. (2010). Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
  231. (2002). Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways.
  232. (1995). Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes.
  233. (2004). Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors.
  234. (1998). Heterodimerization is required for the formation of a functional GABA(B) receptor.
  235. (2001). Heterodimerization of calcium sensing receptors with metabotropic glutamate receptors in neurons.
  236. (2010). Heterogeneity in astrocyte morphology and physiology.
  237. (2009). High extracellular glutamate modulates expression of glutamate transporters and glutamine synthetase in cultured astrocytes.
  238. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.
  239. (1996). Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals.
  240. (2010). Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca 2+ signaling.
  241. (1996). HmGlu1d, a novel splice variant of the human type I metabotropic glutamate receptor.
  242. (2007). Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors.
  243. (1999). Homer 1b regulates the trafficking of group I metabotropic glutamate receptors.
  244. (1998). Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors.
  245. (1998). Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins.
  246. (2002). Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons.
  247. (1997). Homer: a protein that selectively binds metabotropic glutamate receptors.
  248. (2002). Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum.
  249. (2004). Identification and functional roles of metabotropic glutamate receptor-interacting proteins.
  250. (2001). Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.
  251. (2001). Identification of novel alternatively-spliced mRNA isoforms of metabotropic glutamate receptor 6 gene in rat and human retina.
  252. (1998). Identification of the sites of Nlinked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction.
  253. (1999). Identification, cloning and analysis of expression of a new alternatively spliced form of the metabotropic glutamate receptor mGluR1 mRNA1.
  254. (1998). Immunocytochemical localization of the mGluR1b metabotropic glutamate receptor in the rat hypothalamus.
  255. (2001). Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes.
  256. (1996). In vitro ischemia promotes calcium influx and intracellular calcium release in hippocampal astrocytes.
  257. (2005). Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics.
  258. (2010). Increased receptor stimulation elicits differential calcium-sensing receptor(T888) dephosphorylation.
  259. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.
  260. (1991). Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats.
  261. (1990). Inhibition of Ca 2+ and K + channels in sympathetic neurons by neuropeptides and other ganglionic transmitters.
  262. (1996). Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat.
  263. (1999). Inhibition of N-linked glycosylation of the human type 1alpha metabotropic glutamate receptor by tunicamycin: effects on cell-surface receptor expression and function.
  264. (2003). Insights into G protein structure, function, and regulation.
  265. (1957). Interaction at end-plate receptors between different choline derivatives.
  266. (2007). Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses.
  267. (1997). Intracellular calcium oscillations in astrocytes: a highly plastic, bidirectional form of communication between neurons and astrocytes in situ.
  268. (2009). Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts.
  269. (1996). Intramolecular interactions mediate pH regulation of connexin43 channels.
  270. (1996). Ionotropic and metabotropic glutamate receptors show unique postsynaptic, presynaptic, and glial localizations in the dorsal cochlear nucleus.
  271. (2004). Isoform-specific phosphorylation of metabotropic glutamate receptor 5 by protein kinase C (PKC) blocks Ca 2+ oscillation and oscillatory translocation of Ca 2+ -dependent PKC.
  272. (2000). Knopfel T and De Blasi A
  273. (2000). Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice.
  274. (1998). Lanzafame A and Mitchelson F
  275. (2010). Levodopainduced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
  276. (1998). Lifetime regulation of G protein-effector complex: emerging importance of RGS proteins.
  277. (2006). Local potassium signaling couples neuronal activity to vasodilation in the brain.
  278. (1995). Long-lasting changes of calcium oscillations in astrocytes. A new form of glutamate-mediated plasticity.
  279. (2002). Low glial numbers in the amygdala in major depressive disorder.
  280. (2003). Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.
  281. (1993). Mammalian ionotropic glutamate receptors.
  282. (2006). Mammalian RGS proteins: multifunctional regulators of cellular signalling.
  283. (2005). Mechanisms of ammonia-induced astrocyte swelling.
  284. (2003). Membrane topology of a metabotropic glutamate receptor.
  285. (2008). Metabotropic glutamate 1 receptor: current concepts and perspectives.
  286. (2001). Metabotropic glutamate receptor 5 mediates the potentiation of Nmethyl-D-aspartate responses in medium spiny striatal neurons.
  287. (1992). Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine.
  288. (1997). Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas.
  289. (1997). Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation.
  290. (1994). Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat.
  291. (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov
  292. (2000). Metabotropic glutamate receptors in acutely isolated hippocampal astrocytes: developmental changes of mGluR5 mRNA and functional expression.
  293. (2009). Metabotropic glutamate receptors in the control of neuronal activity and as targets for development of anti-epileptogenic drugs.
  294. (1999). Metabotropic glutamate receptors: electrophysiological properties and role in plasticity.
  295. (2010). Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology Nimmerjahn A
  296. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease.
  297. (1994). Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity.
  298. (2006). Metabotropic glutamate receptors.
  299. (2003). Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents.
  300. (1999). mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats.
  301. (2007). mGluR5 stimulates gliotransmission in the nucleus accumbens.
  302. (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP.
  303. (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation.
  304. (1983). Modification of the binding properties of muscarinic receptors by gallamine.
  305. (1993). Modulation of calcium currents by a metabotropic glutamate receptor involves fast and slow kinetic components in cultured hippocampal neurons.
  306. (2005). Molecular and functional characterisation of glutamate transporters in rat cortical astrocytes exposed to a defined combination of growth factors during in vitro differentiation.
  307. (1994). Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction.
  308. (1993). Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate.
  309. (2002). Molecular determinants of high affinity binding to group III metabotropic glutamate receptors.
  310. (2001). Molecular determinants of metabotropic glutamate receptor 1B trafficking.
  311. (2008). Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
  312. (2004). Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.
  313. (1996). Molecular mechanisms of the protein serine/threonine phosphatases.
  314. (2005). Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 97:202-213.
  315. (1999). Molecular tinkering of G protein-coupled receptors: an evolutionary success.
  316. (1995). Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1.
  317. (2009). Morphological evidence for vesicular glutamate release from astrocytes.
  318. (1999). Mutagenesis and modeling of the GABAB receptor extracellular domain support a venus flytrap mechanism for ligand binding.
  319. (2003). Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.
  320. (2003). Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine.
  321. (1998). Mutational analysis of the cysteines in the extracellular domain of the human Ca 2+ receptor: effects on cell surface expression, dimerization and signal transduction.
  322. (2000). Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation.
  323. (2008). N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro2H-isoindol-2-yl)methyl]phenyl}-2-hy droxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
  324. (1987). Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
  325. (2003). Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation.
  326. (2004). Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors.
  327. (2009). Neuroscience: Glia - more than just brain glue.
  328. (2010). Neuroscience: Settling the great glia debate.
  329. (2005). New concepts in drug discovery: collateral efficacy and permissive antagonism.
  330. (2003). New roles for astrocytes: redefining the functional architecture of the brain.
  331. (2006). New targets for pharmacological intervention in the glutamatergic synapse.
  332. (1996). News on glutamate receptors in glial cells.
  333. (2003). NFAT functions as a working memory of Ca 2+ signals in decoding Ca 2+ oscillation.
  334. (2003). NFAT4 is expressed in primary astrocytes and activated by glutamate.
  335. (2005). NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin.
  336. (2005). Nonfunctional glial proteins in tripartite synapses: a pathophysiological model of schizophrenia.
  337. (2009). Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling.
  338. (2005). oscillations.
  339. (2003). P2X7 receptor-mediated release of excitatory amino acids from astrocytes.
  340. (1997). Palmitoylation of muscarinic acetylcholine receptor m2 subtypes: reduction in their ability to activate G proteins by mutation of a putative palmitoylation site, cysteine 457, in the carboxyl-terminal tail.
  341. (2000). Pharmacological and functional characterization of astrocytic GABA transport: a short review.
  342. (1997). Pharmacology and functions of metabotropic glutamate receptors.
  343. (2007). Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology.
  344. (1997). Phosphorylation and calmodulin binding of the metabotropic glutamate receptor subtype 5 (mGluR5) are antagonistic in vitro.
  345. (2008). Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo.
  346. (2009). Phosphorylation of the homer-binding domain of group I metabotropic glutamate receptors by cyclin-dependent kinase 5.
  347. (2009). Phosphorylation-independent regulation of metabotropic glutamate receptor 5 desensitization and internalization by G protein-coupled receptor kinase 2 in neurons.
  348. (2002). Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2.
  349. (2004). PKC at a glance.
  350. (2001). PKC phosphorylation of a conserved serine residue in the C-terminus of group III metabotropic glutamate receptors inhibits calmodulin binding.
  351. (2007). PKCepsilon induces astrocytic differentiation of multipotential neural precursor cells.
  352. (2007). PKCepsilon upregulates voltage-dependent calcium channels in cultured astrocytes.
  353. (2008). Plasticity-dependent changes in metabotropic glutamate receptor expression at excitatory hippocampal synapses.
  354. (2007). Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-Daspartate antagonist-induced alteration of neuronal firing in prefrontal cortex.
  355. (2001). Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.
  356. (2004). Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential.
  357. (1992). Positive feedback of glutamate exocytosis by metabotropic presynaptic receptor stimulation.
  358. (1990). Potassium conductances in hippocampal neurons blocked by excitatory amino-acid transmitters.
  359. (1998). Pozzan T and Volterra A
  360. (2008). PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail).
  361. (1996). Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody.
  362. (1998). Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV.
  363. (1996). Presynaptic localization of a metabotropic glutamate receptor, mGluR4a, in the cerebellar cortex: a light and electron microscope study in the rat.
  364. (1995). Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA.
  365. (2006). Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
  366. (1991). Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
  367. (2005). Protein kinase C epsilon mediates angiotensin IIinduced activation of beta1-integrins in cardiac fibroblasts.
  368. (1998). Protein kinase C eta mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes.
  369. (2007). Protein kinase C-mediated phosphorylation of the calcium-sensing receptor is stimulated by receptor activation and attenuated by calyculin-sensitive phosphatase activity.
  370. (2008). Protein kinase Cepsilon: function in neurons.
  371. (2002). Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains.
  372. (2009). Purinoceptors on neuroglia.
  373. (2010). Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia. British Pharmacological Society Winter Meeting London 14th-16th
  374. (2007). Recent progress in the development of allosteric modulators of mGluR5. Curr Opin Drug Discov Devel
  375. (1999). Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.
  376. (1986). Receptor-mediated inositol phospholipid hydrolysis in astrocytes.
  377. (2005). Receptors coupled to heterotrimeric G proteins of the G12 family.
  378. (2000). Reciprocal communication systems between astrocytes and neurones.
  379. (1994). Reduction of resting K + current by metabotropic glutamate and muscarinic receptors in rat CA3 cells: mediation by Gproteins.
  380. (1998). Regional expression and regulation of alternative forms of mRNAs derived from two distinct transcription initiation sites of the rat mGluR5 gene.
  381. (2006). Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis.
  382. (2008). Regulation of pH in the mammalian central nervous system under normal and pathological conditions: facts and hypotheses.
  383. (2010). Regulation of type 5 metabotropic glutamate receptor-stimulated Ca oscillations in rat cerebrocortical astrocytes by
  384. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
  385. (2008). Rescue of behavioral phenotype and neuronal protrusion morphology
  386. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
  387. (2001). RGS12 and RGS14 GoLoco motifs are G alpha(i) interaction sites with guanine nucleotide dissociation inhibitor Activity.
  388. (1997). RGS4 and GAIP are GTPase-activating proteins for Gq alpha and block activation of phospholipase C beta by gamma-thio-GTP-Gq alpha.
  389. (1998). Rhodopsin: a prototypical G protein-coupled receptor.
  390. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome.
  391. (2006). Role of astrocytes in cerebrovascular regulation.
  392. (1998). Role of protein kinase C phosphorylation in rapid desensitization of metabotropic glutamate receptor 5.
  393. (2005). Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons.
  394. (1993). Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination.
  395. (1998). Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation.
  396. (2002). Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling.
  397. (1995). Roles of specific metabotropic glutamate receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability.
  398. (2008). Schizophrenia therapy: beyond atypical antipsychotics.
  399. (2004). Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell.
  400. (1993). Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976.
  401. (1998). Sensitivity of CaM kinase II to the frequency of Ca 2+ oscillations.
  402. (1991). Sequence and expression of a metabotropic glutamate receptor.
  403. (2009). Serine/threonine phosphatases: mechanism through structure.
  404. (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.
  405. (2007). Seven transmembrane receptors: something old, something new.
  406. (2002). Seven-transmembrane receptors.
  407. (2007). Sexton PM and Christopoulos A
  408. (1992). Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells.
  409. (2000). Signaling of G(alpha)(12) family of G proteins through a tyrosine kinase and a Ras-GAP. Trends Cardiovasc Med
  410. (1992). Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function.
  411. (2009). Sorting out astrocyte physiology from pharmacology. Annu Rev Pharmacol Toxicol
  412. (2001). Spatialtemporal patterning of metabotropic glutamate receptor-mediated inositol 1,4,5-triphosphate, calcium, and protein kinase C oscillations: protein kinase C-dependent receptor phosphorylation is not required.
  413. (1995). Staurosporine induces astrocytic phenotypes and differential expression of specific PKC isoforms in C6 glial cells.
  414. (2004). Stimulus- and cell-type-specific release of purines in cultured rat forebrain astrocytes and neurons.
  415. (2008). Store-operated Ca 2+ entry in astrocytes: different spatial arrangement of endoplasmic reticulum explains functional diversity in vitro and in situ.
  416. (2006). Structural and molecular interactions of CCR5 inhibitors with CCR5.
  417. (2000). Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor.
  418. (1994). Structural determinants for activation of the alpha-subunit of a heterotrimeric G protein.
  419. (2008). Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357.
  420. (2002). Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd 3+ .
  421. (2001). Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors.
  422. (2011). Structure and function of an irreversible agonist-beta(2) adrenoceptor complex.
  423. (2008). Structure of a beta1-adrenergic Gprotein-coupled receptor.
  424. (2011). Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor.
  425. (1989). Structure of the adrenergic and related receptors.
  426. (2007). Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets 8:169-184.
  427. (2007). Structures of the extracellular regions of the group II/III metabotropic glutamate receptors.
  428. (2008). Sub-micromolar increase in [Ca( 2+ )](i) triggers delayed exocytosis of ATP in cultured astrocytes.
  429. (1992). Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phospholipase C.
  430. (1978). Suppression of histone deacetylation in vivo and in vitro by sodium butyrate.
  431. (2005). Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
  432. (2006). Synaptic scaling mediated by glial TNF-alpha.
  433. (2009). Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice.
  434. (2006). Target cell-specific modulation of neuronal activity by astrocytes.
  435. (2007). Targeting the protein kinase C family: are we there yet?
  436. (1996). The 2.0 A crystal structure of a heterotrimeric G protein.
  437. (1993). The 2.2 A crystal structure of transducinalpha complexed with GTP gamma S.
  438. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.
  439. (1998). The 45 kDa form of glucose transporter 1 (GLUT1) is localized in oligodendrocyte and astrocyte but not in microglia in the rat brain.
  440. (2004). The activation mechanism of class-C G-protein coupled receptors.
  441. (2008). The astrocyte odyssey.
  442. (2004). The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
  443. (1996). The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists.
  444. (2005). The CCR5 receptorbased mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.
  445. (2007). The classical complement cascade mediates CNS synapse elimination.
  446. (1996). The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy.
  447. (1995). The expression of two splice variants of metabotropic glutamate receptor subtype 5 in the rat brain and neuronal cells during development.
  448. (1998). The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 49:15-29.
  449. (2007). The G protein-coupled receptor subset of the rat genome.
  450. (2003). The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.
  451. (2009). The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature.
  452. (1993). The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins.
  453. (1993). The metabotropic glutamate receptor (mGluR1 alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction.
  454. (1997). The metabotropic glutamate receptor mGluR5 induces calcium oscillations in cultured astrocytes via protein kinase C phosphorylation.
  455. (1995). The metabotropic glutamate receptors: structure and functions.
  456. (1995). The metabotropic glutamate receptors: their second intracellular loop plays a critical role in the G-protein coupling specificity.
  457. (2004). The mGluR theory of fragile X mental retardation.
  458. (2008). The mystery and magic of glia: a perspective on their roles in health and disease.
  459. (2000). The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors.
  460. (2007). The pipeline and future of drug development in schizophrenia.
  461. (1997). The role of glutamate transporters in glutamate homeostasis in the brain.
  462. (1996). The second intracellular loop of metabotropic glutamate receptor 1 cooperates with the other intracellular domains to control coupling to G-proteins.
  463. (2003). The second intracellular loop of metabotropic glutamate receptors recognizes C termini of G-protein alpha-subunits.
  464. (2011). The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor.
  465. (2009). The structure and function of G-protein-coupled receptors.
  466. (2007). The trick of the tail: protein-protein interactions of metabotropic glutamate receptors.
  467. (1995). The two-state model of receptor activation.
  468. (2000). The versatility and universality of calcium signalling.
  469. (2005). Thrombospondins are astrocytesecreted proteins that promote CNS synaptogenesis.
  470. (1997). Transcription factors of the NFAT family: regulation and function.
  471. (1999). Tripartite synapses: glia, the unacknowledged partner.
  472. (2008). Two conventional protein kinase C isoforms, alpha and beta I, are involved in the ATPinduced activation of volume-regulated anion channel and glutamate release in cultured astrocytes.
  473. (1991). Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits.
  474. (2000). Uncovering molecular mechanisms involved in activation of G protein-coupled receptors.
  475. (2008). What is the role of astrocyte calcium in neurophysiology?
  476. (2007). When a G protein-coupled receptor does not couple to a G protein.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.